Oncology Institute (TOI) Competitors

Oncology Institute (NASDAQ:TOI) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, community ranking, profitability, institutional ownership, valuation and earnings.

Does the media prefer TOI or CSTL?

In the previous week, Castle Biosciences had 7 more articles in the media than Oncology Institute. MarketBeat recorded 10 mentions for Castle Biosciences and 3 mentions for Oncology Institute. Castle Biosciences' average media sentiment score of 1.05 beat Oncology Institute's score of 0.98 indicating that Castle Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncology Institute	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Castle Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, TOI or CSTL?

Oncology Institute has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of TOI or CSTL?

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 8.5% of Oncology Institute shares are owned by insiders. Comparatively, 7.2% of Castle Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is TOI or CSTL more profitable?

Castle Biosciences has a net margin of 1.95% compared to Oncology Institute's net margin of -17.63%. Castle Biosciences' return on equity of 1.47% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-17.63%	-186.83%	-34.58%
Castle Biosciences	1.95%	1.47%	1.27%

Which has preferable valuation and earnings, TOI or CSTL?

Castle Biosciences has lower revenue, but higher earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Castle Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$393.41M	0.54	-$83.07M	-$0.71	-3.93
Castle Biosciences	$332.07M	1.68	-$57.47M	$0.62	31.15

Do analysts recommend TOI or CSTL?

Castle Biosciences has a consensus price target of $38.75, indicating a potential upside of 100.67%. Given Castle Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Castle Biosciences is more favorable than Oncology Institute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Castle Biosciences	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in TOI or CSTL?

Castle Biosciences received 88 more outperform votes than Oncology Institute when rated by MarketBeat users. However, 66.67% of users gave Oncology Institute an outperform vote while only 64.79% of users gave Castle Biosciences an outperform vote.

Company	Underperform	Outperform
Oncology Institute	Outperform Votes 4 66.67%	Underperform Votes 2 33.33%
Castle Biosciences	Outperform Votes 92 64.79%	Underperform Votes 50 35.21%

Summary

Castle Biosciences beats Oncology Institute on 15 of the 18 factors compared between the two stocks.